Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358452 | 0.82 | CYP1A2 (0.73) | CYP1A2CYP2C9GRIN1GRIN2BMAOB | |
| SCHEMBL5046640 | 0.82 | CYP1A2 (0.73) | CYP1A2CYP2C9GRIN1GRIN2BMAOB | |
| SCHEMBL2675960 | 0.77 | CYP1A2 (0.51) | CYP1A2CYP2C9PARP1GRIN2DGRIN3B | |
| Urea SCHEMBL29193198 | 0.77 | PARP1 (0.67) | CYP1A2CYP2C9PARP1KMT2ANPC1 | |
| SCHEMBL5426212 | 0.77 | LCK (0.52) | PARP1MAOBFBP1CYP3A4MAOA | |
| SCHEMBL2825728 | 0.75 | NFE2L2 (0.56) | CYP1A2PARP1MAOBCHRM5FBP1 | |
| SCHEMBL13358871 | 0.75 | HSD17B3 (0.58) | PARP1MAOBSMN1; SMN2MAPTCYP2D6 | |
| SCHEMBL9899535 | 0.75 | TP53 (0.47) | PARP1KMT2AMEN1ALDH1A1POLB | |
| Carbamic Acid SCHEMBL8861730 | 0.75 | PARP1 (0.64) | CYP1A2CYP2C9PARP1KMT2ANPC1 | |
| SCHEMBL5598564 | 0.73 | CYP1A2 (1.00) | CYP1A2CYP2C9MAOBFBP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CYP1A2 1093/4885CYP2C9 1594/4885PARP1 2471/4885 |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | CYP1A2 4066/4885CYP2C9 4811/4885PARP1 2798/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | CYP1A2 811/4885CYP2C9 1239/4885PARP1 821/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | CYP1A2 1882/4885CYP2C9 931/4885PARP1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.